Goldman Sachs Maintains Neutral on Oscar Health, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich maintains a Neutral rating on Oscar Health (OSCR) and raises the price target from $16 to $21.

May 09, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Oscar Health but raises the price target from $16 to $21.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the stock might not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100